Penumbra (PEN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $1.01
- Estimate
- $1.18
- Surprise
- -14.4%
- Revenue (period 2026-06-30)
- $390.0M
- Score at report (before → after)
- 4.7 → 5.0/10
Revenue source: mixed.
How the report landed
Penumbra (PEN) missed the $1.18 estimate with adjusted EPS of $1.01 — a large 14.4% shortfall. TrendMatrix's engine moved from Data Issue (4.7/10) to Sell at 5.0/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PEN Sell at 5.0/10.
2 of the last 4 quarters beat the estimate; this quarter's -14.4% surprise compares with a -1.9% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Wide economic moat
What argues against it
- Concentration risk — Product: thrombectomy products
- Concentration risk — Supplier: single or limited number of suppliers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $319.72
- Price target
- $367.68
- Stop
- $315.98
- Upside to target
- +15.0%
The stock trades at 78.7× trailing but 52.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
PEN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $12.58B
- P/E (fwd)
- 52.1
- P/E (ttm)
- 78.7
- 52-week range
- $221.26–$362.41
- Off 52-week high
- 11.8%
- RSI (14)
- 45
- Volume vs avg
- 1.21×
- Score today
- 5.0/10